Earnings Feed
Start Free
ZEVRA THERAPEUTICS, INC.·4

Feb 2, 5:19 PM ET

Schafer Joshua 4

4 · ZEVRA THERAPEUTICS, INC. · Filed Feb 2, 2026

Research Summary

AI-generated summary of this filing

Updated

ZVRA (Zevra Therapeutics) CCO Joshua Schafer Sells Shares & Exercises Options

What Happened

  • Joshua Schafer, Chief Commercial Officer of Zevra Therapeutics (ZVRA), sold 3,375 shares in an open-market transaction on Jan 30, 2026 for a weighted-average price of $8.83, generating about $29,800. Around Jan 30–31, he also had multiple derivative transactions: exercises/conversions that resulted in 11,333 shares (Jan 30) and 35,334 shares (Jan 31) being acquired and then reported as disposed at $0 (consistent with net settlement/withholding or immediate transfer of vested shares).
  • On Jan 29, 2026 Schafer was awarded two sets of restricted stock units (RSUs) — 37,500 and 75,000 RSUs (derivative awards, $0 exercise price) — and received a stock option grant (see footnotes for vesting schedules).

Key Details

  • Transaction dates and prices:
    • Jan 30, 2026: Open-market sale of 3,375 shares at a weighted-average $8.83 (prices in the trades ranged $8.64–$9.03) — proceeds ≈ $29,800 (F3).
    • Jan 30, 2026: Exercise/conversion of 11,333 derivative units (acquired) and 11,333 derivative shares reported disposed at $0 (M).
    • Jan 31, 2026: Exercise/conversion of 35,334 derivative units (acquired) and 35,334 derivative shares reported disposed at $0 (M).
    • Jan 29, 2026: Grants of 37,500 RSUs and 75,000 RSUs (A) and a stock option grant (see F4–F7 and F5 for vesting).
  • Shares owned after the transactions: Not specified in the provided filing.
  • Notable footnotes:
    • F1: Each RSU represents a contingent right to one common share.
    • F2: A 10b5-1 trading plan was adopted on 3/27/2025 (suggests sales may have followed a preset plan).
    • F3: Sale executed in multiple trades; weighted-average price reported.
    • F4–F7 and F5: Describe vesting/settlement schedules for the RSUs and the option grant; portions of RSUs vested/settled on Jan 30–31 as noted.
  • Filing timeliness: Form filed 2026-02-02; filing appears to be within the standard Form 4 reporting window for these transactions (no late-filing flag provided).

Context

  • The filing shows both awards/grants (RSUs and an option grant) and a small open-market sale. The large RSU/option activity reflects compensation and vesting mechanics rather than a simple buy/sell signal.
  • The exercises/conversions followed by $0 disposals are commonly due to net share settlement or shares withheld to cover taxes or option exercise costs — not necessarily an independent cash sale. The only reported cash sale was the 3,375-share open-market sale (~$29.8K), which may have been executed under the 10b5-1 plan.

Insider Transaction Report

Form 4
Period: 2026-01-29
ZEVRA THERAPEUTICS, INC.ZVRA
Schafer Joshua
CCO
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-01-30+11,333→ 40,819 total
  • Sale

    Common Stock

    [F2][F3]
    2026-01-30$8.83/sh−3,375$29,800→ 37,444 total
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-01-31+35,334→ 72,778 total
  • Award

    Restricted Stock Unit

    [F1][F4]
    2026-01-29+37,500→ 37,500 total
    → Common Stock (37,500 underlying)
  • Award

    Stock Option (right to buy)

    [F5]
    2026-01-29+75,000→ 75,000 total
    Exercise: $8.86Exp: 2036-01-28→ Common Stock (75,000 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    [F1][F6]
    2026-01-30−11,333→ 22,667 total
    → Common Stock (11,333 underlying)
  • Exercise/Conversion

    Restricted Stock Unit

    [F1][F7]
    2026-01-31−35,334→ 35,333 total
    → Common Stock (35,334 underlying)
Footnotes (7)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
  • [F2]Adoption date of referenced 10b5-1(c) plan is: 3/27/2025.
  • [F3]This transaction was executed in multiple trades at prices ranging from $8.64 to $9.03. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F4]The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date.
  • [F5]Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.
  • [F6]One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the shares will vest and settle in equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date.
  • [F7]One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject to the Reporting person's continued service through such vesting date.
Signature
/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Joshua Schafer|2026-02-02

Documents

1 file
  • 4
    wk-form4_1770070744.xmlPrimary

    FORM 4